- Sinovac Biotech ( NASDAQ: SVA ) said its COVID-19 vaccine CoronaVac was approved by the Brazilian Health Regulatory Agency (Anvisa) for emergency use in children three to five years old, on July 13.
- The Chinese company said the children will receive the same dose that is already applied to minors aged six to 17 years and adults and there is no restriction on the application for immunosuppressed children aged three to five years.
- The vaccine was authorized for emergency use for adults in Brazil on Jan. 17, 2021 and to children and adolescents six to 17 years of age on Jan. 20, 2022, the company noted.
- Sinovac said that as of July 14, CoronaVac is authorized for emergency use in minors in 14 countries and regions, including Chile, Colombia, Ecuador, Brazil, and certain countries/region in Asia and Africa.
For further details see:
Sinovac COVID-19 vaccine gets emergency use nod in Brazil for children aged 3-5 years